Relationship between matrix metalloproteinase-9 and oxidative stress in drug-free male schizophrenia: A case control study

Clinical Chemistry and Laboratory Medicine

Volumn 54, Issue 3, 2016, Pages 447-452

  Devanarayanan, Sivasankar ^a   Nandeesha, Hanumanthappa ^a   Kattimani, Shivanand ^a   Sarkar, Siddharth ^a  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

malondialdehyde; matrix metalloproteinase 9; positive and negative syndrome score; schizophrenia; total antioxidant status

Indexed keywords

ANTIOXIDANT; GELATINASE B; MALONALDEHYDE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSESSMENT; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DRUG EXPOSURE; HUMAN; MALE; NERVE CELL PLASTICITY; OXIDATIVE STRESS; PATHOGENESIS; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHIZOPHRENIA; BIOLOGICAL MODEL; BLOOD; CASE CONTROL STUDY; ENZYMOLOGY; PATHOPHYSIOLOGY; STATISTICAL MODEL;

ADULT; CASE-CONTROL STUDIES; HUMANS; LINEAR MODELS; MALE; MALONDIALDEHYDE; MATRIX METALLOPROTEINASE 9; MODELS, BIOLOGICAL; OXIDATIVE STRESS; SCHIZOPHRENIA;

EID: 84958755999     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2015-0212     Document Type: Article

References (33)

1. MacDonald AW, Schulz SC. What we know: findings that every theory of schizophrenia should explain. Schizophr Bull 2009;35:493-508.
2. Pedrini M, Massuda R, Fries GR, de Bittencourt Pasquali MA, Schnorr CE, Moreira JC, et al. Similarities in serum oxidative stress markers and inflammatory cytokines in patients with overt schizophrenia at early and late stages of chronicity. J Psychiatr Res 2012;46:819-24.
3. Ethell IM, Ethell DW. Matrix metalloproteinases in brain development and remodeling: synaptic functions and targets. J Neurosci Res 2007;85:2813-23.
4. Halade GV, Jin YF, Lindsey ML. Matrix metalloproteinase (MMP)-9: a proximal biomarker for cardiac remodeling and a distal biomarker for inflammation. Pharmacol Ther 2013;139:32-40.
5. Nagy V, Bozdagi O, Matynia A, Balcerzyk M, Okulski P, Dzwonek J, et al. Matrix metalloproteinase-9 is required for hippocampal late-phase long-term potentiation and memory. J Neurosci 2006;26:1923-34.
6. Okulski P, Jay TM, Jaworski J, Duniec K, Dzwonek J, Konopacki FA, et al. TIMP-1 abolishes MMP-9-dependent long-lasting long-term potentiation in the prefrontal cortex. Biol Psychiatry 2007;62:359-62.
7. Leib SL, Clements JM, Lindberg RL, Heimgartner C, Loeffler JM, Pfister LA, et al. Inhibition of matrix metalloproteinases and tumour necrosis factor alpha converting enzyme as adjuvant therapy in pneumococcal meningitis. Brain 2001;124:1734-42.
8. Wilczynski GM, Konopacki FA, Wilczek E, Lasiecka Z, Gorlewicz A, Michaluk P, et al. Important role of matrix metalloproteinase 9 in epileptogenesis. J Cell Biol 2008;180:1021-35.
9. Ng F, Berk M, Dean O, Bush AI. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 2008;11;851-76.
10. Yao JK, Keshavan MS. Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. Antioxid Redox Signal 2011;15:2011-35.
11. Mahadik S P, Evans D, Lal H. Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2001;25:463-93.
12. Khan MM, Evans DR, Gunna V, Scheffer RE, Parikh VV, Mahadik SP. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr Res 2002;58:1-10.
13. Fukunaga K, Yoshida M, Nakazono N. A simple, rapid, highly sensitive and reproducible quantification method for plasma malondialdehyde by high-performance liquid chromatography. Biomed Chromatogr 1998;12:300-3.
14. Boskovic M, Vovk T, Plesnicar BK, Grabnar I. Oxidative stress in schizophrenia. Curr Neuropharmacol 2011;9:301-12.
15. Ranjekar PK, Hinge A, Hegde MV, Ghate M, Kale A, Sitasawad S, et al. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res 2003;121:109-22.
16. Evans DR, Parikh VV, Khan MM, Coussons C, Buckley PF, Mahadik SP. Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. Prostaglandins Leukot Essent Fatty Acids 2003;69:393-9.
17. Virit O, Altindag A, Yumru M, Dalkilic A, Savas HA, Selek S, et al. A defect in the antioxidant defense system in schizophrenia. Neuropsychobiology 2009;60:87-93.
18. Ustundag B, Atmaca M, Kirtas O, Selek S, Metin K, Tezcan E. Total antioxidant response in patients with schizophrenia. Psychiatry Clin Neurosci 2006;60:458-64.
19. Agarwal R, Chase SD. Rapid fluorimetric-liquid chromatographic determination of malondialdehyde in biological samples. J Chromatogr B Analyt Technol Biomed Life Sci 2002;775:121-6.
20. Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of 'antioxidant power' the FRAP assay. Anal Biochem 1996;239:70-6.
21. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.
22. Yabluchanskiy A, Ma Y, Iyer RP, Hall ME, Lindsey ML. Matrix metalloproteinase-9: many shades of function in cardiovascular disease. Physiology 2013;28:391-403.
23. Gottschall PE, Deb S. Regulation of matrix metalloproteinase expressions in astrocytes, microglia and neurons. Neuroimmunomodulation 1996;3:69-75.
24. Kaczmarek L, Lapinska-Dzwonek J, Szymczak S. Matrix metalloproteinases in the adult brain physiology: a link between c-Fos, AP-1 and remodeling of neuronal connections? EMBO J 2002;21:6643-8.
25. Groszewska A, Kapelski P, Skibińska M, Hauser J. Family based association study of MMP-9 gene-1562 C & gt;T polymorphism in schizophrenia. Psychiatr Pol 2011;45:317-24.
26. Han H, He X, Tang J, Liu W, Liu K, Zhang J, et al. The C(-1562)T polymorphism of matrix metalloproteinase-9 gene is associated with schizophrenia in China. Psychiatry Res 2011;190:163-4.
27. Yamamori H1, Hashimoto R, Ishima T, Kishi F, Yasuda Y, Ohi K, et al. Plasma levels of mature brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) in treatment-resistant schizophrenia treated with clozapine. Neurosci Lett 2013;556:37-41.
28. Niitsu T, Ishima T, Yoshida T, Hashimoto T, Matsuzawa D, Shirayama Y, et al. A positive correlation between serum levels of mature brain-derived neurotrophic factor and negative symptoms in schizophrenia. Psychiatry Res 2014;215:268-73.
29. Stephan KE, Baldeweg T, Friston KJ. Synaptic plasticity and dysconnection in schizophrenia. Biol Psychiatry 2006;59:929-39.
30. Hall J, Trent S, Thomas KL, O'Donovan MC, Owen MJ. Genetic risk for schizophrenia: convergence on synaptic pathways involved in plasticity. Biol Psychiatry 2015;77:52-8.
31. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. J Clin Invest 1996;98:2572-9.
32. Kameda K, Matsunaga T, Abe N, Hanada H, Ishizaka H, Ono H. Correlation of oxidative stress with activity of matrix metalloproteinase in patients with coronary artery disease. Possible role for left ventricular remodelling. Eur Heart J 2003;24:2180-5.
33. Stawarski M, Stefaniuk M, Wlodarczyk J. Matrix metalloproteinase-9 involvement in the structural plasticity of dendritic spines. Front Neuroanat 2014;8:1-15.